Showing 651-660 of 1119 results for "".
- In With the Old: Curettage and Cryosurgery Still Effective for BCChttps://practicaldermatology.com/news/in-with-the-old-curettage-and-cryosurgery-still-effective-for-bcc/2461815/The combination of curettage and cryosurgery is a safe and effective treatment method for basal cell carcinoma, and now, a new study presents the results from testing different variants of the method. The current study, which appears in the Journal of the American Academy of Dermat
- HS Pipeline Update: HS Patients Taking Nanobody Sonelokimab Hit HiSCR 75 as Early as Week 12https://practicaldermatology.com/news/hs-pipeline-update-hs-patients-taking-nanobody-sonelokimab-hit-hiscr-75-as-early-as-week-12/2461806/Nanobody Sonelokimab is looking good in patients with moderate-to-severe hidradenitis suppurativa (HS), according to topline Phase 2 results from MoonLake Immunotherapeutics. Nanobodies are antibody-derived targeted therapies. They consist of one or more domains based on
- Does IL-17 Play a Role in Skin Aging?https://practicaldermatology.com/news/does-il-17-play-a-role-in-skin-aging/2461770/Interleukin (IL)-17 may plays a central role in skin aging, according to research from Institute for Research in Biomedicine (IRB Barcelona) in collaboration with the National Center for Genomic Analysis (CNAG). The study, which was led by Dr. Guiomar Solanas, Dr. Salvador Azn
- Melanoma Metastasis Discovery: Skin Cancer Rewires Energy Systems to Spreadhttps://practicaldermatology.com/news/melanoma-metastasis-discovery-skin-cancer-rewires-energy-systems-to-spread/2461743/Melanoma skin cancer cells may rewire their internal power systems to drive their spread to other parts of the body, a new study suggests. The research, led by investigators at Barts Cancer Institute, Queen Mary Unive
- Orlucent Receives FDA Breakthrough Device Designation for Handheld Mole Imaging Systemhttps://practicaldermatology.com/news/orlucent-receives-fda-breakthrough-device-designation-for-handheld-mole-imaging-system/2461733/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Orlucent’s Skin Fluorescence Imaging System. The Orlucent system is a handheld point-of-care molecular-based imaging system designed to noninvasively identify and clinically assess the pres
- FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with DEBhttps://practicaldermatology.com/news/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-deb/2461732/The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) g
- AI In Action: Machine Learning Algorithms May Aid Diagnosis and Treatment of ADhttps://practicaldermatology.com/news/ai-in-action-machine-learning-algorithms-may-aid-diagnosis-and-treatment-of-ad/2461726/Researchers have developed six relatively stable and reliable diagnosis and efficacy evaluation prediction models for atopic dermatitis (AD) based on a machine learning algorithm. Songjiang Wu, a PhD candidate in dermatology from Third Xiangya Hospital at the Central South University in
- News You Can Use: MIPS Hardship Exception Available Nowhttps://practicaldermatology.com/news/news-you-can-use-mips-hardship-exception-available-now/2461702/Physicians may now apply for an Extreme and Uncontrollable Circumstances hardship exception to avoid an up to 9% penalty in the Merit-based Incentive Payment System (MIPS) thanks to advocacy from the American Medical Association and organized medicine about the ongoing impacts of the COVID-19 pub
- Resilia Pharmaceuticals Announces Return to Market of Neosalus Cream and Neosalus Lotionhttps://practicaldermatology.com/news/resilia-pharmaceuticals-announces-return-to-market-of-neosalus-cream-and-neosalus-lotion/2461697/Resilia Pharmaceuticals, Inc.’s Neosalus Cream and Neosalus Lotion are back. These products had not been available due to supply chain disruptions that occurred as a result of the COVID-19 public health crisis. Both Neosalus Lotion and Neosalus Cream use paten
- Survey: Gen Z and Millennial Men Fall Short on Face Washing, Skin Carehttps://practicaldermatology.com/news/survey-gen-z-and-millennial-men-fall-short-on-face-washing-skin-care/2461656/Many Gen Z and millennial men would rather going on a bad date than take care of their skin, according to a new survey conducted by OnePoll on behalf of CeraVe. In a recent survey of 2,000 men ages 18–26 and 27–42, two in five (42%) revealed they need someone to confront the